High-dose continuous infusion plus pulse interleukin-2 and famotidine in melanoma

Cancer Biotherapy and Radiopharmaceuticals

Volumn 19, Issue 6, 2004, Pages 770-775

  Quan Jr , Walter ^a,d   Ramirez, Maria ^b   Taylor, W Chris ^b   Vinogradov, Mikhail ^b   Khan, Nawazish ^b   Jackson, Shawn ^c  

^a MEDICAL COLLEGE OF OHIO   (United States)

^b EAST CAROLINA UNIVERSITY   (United States)

^c University of Texas Medical Branch School of Medicine   (United States)

^d Ruppert Health Center   (United States)

Author keywords

Famotidine; Interleukin 2; Lymphokine Activated Killer (LAK) cells; Melanoma

Indexed keywords

CD56 ANTIGEN; DILTIAZEM; DOPAMINE; FAMOTIDINE; IBUPROFEN; INTERLEUKIN 2; ONDANSETRON; PARACETAMOL;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONTINUOUS INFUSION; CYTOTOXIC LYMPHOCYTE; CYTOTOXICITY; DIARRHEA; DRUG MEGADOSE; DRUG PULSE THERAPY; DRUG WITHDRAWAL; FEMALE; FEVER; FLU LIKE SYNDROME; HEART ATRIUM FIBRILLATION; HUMAN; HYPOCALCEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; HYPOTENSION; KIDNEY DYSFUNCTION; LUNG EDEMA; LYMPH NODE BIOPSY; LYMPHOCYTIC INFILTRATION; LYMPHOKINE ACTIVATED KILLER CELL; MALAISE; MALE; MELANOMA; METABOLIC ACIDOSIS; METASTASIS; NAUSEA; PREMEDICATION; PRIORITY JOURNAL; RIGOR; STOMATITIS; SUBCUTANEOUS TISSUE; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; DRUG THERAPY, COMBINATION; FAMOTIDINE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INTERLEUKIN-2; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPH NODES; MALE; MELANOMA; MIDDLE AGED; PULSE; SKIN NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 14044253548     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2004.19.770     Document Type: Article

References (32)

1. Atkins MB, Kunkel L, Sznol M, et al. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: Long-term survival update. Cancer J Sci Am 2000;6(Suppl. 1):S11.
2. Rosenberg SA, Yang JC, Topalian SL, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2. JAMA 1994;271:907.
3. Hawkins MJ. Interleukin-2 antitumor and effector cell responses. Semin Oncol 1993;20(Suppl. 9):52.
4. Papa MZ, Mule JJ, Rosenberg SA. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin in vivo: Successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three distinct histologic types. Cancer Res 1986;46:4973.
5. Margolin KA, Rayner AA, Hawkins MJ, et al. Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: Analysis of toxicity and management guidelines. J Clin Oncol 1989;7:486.
6. Siegel JP, Puri RK. Interleukin-2 toxicity. J Clin Oncol 1991;9:694.
7. Dillman RO, Oldham RK, Tauer KW, et al. Continuous interleukin-2 and lymphokine-activated killer cells for advanced cancer: A National Biotherapy Study Group trial. J Clin Oncol 1991;9:1233.
8. Dillman RO, Oldham RK, Barth NM, et al. Continuous interleukin-2 and tumor-infiltrating lymphocytes as treatment of advanced melanoma. A National Biotherapy Study Group trial. Cancer 1991;68:1.
9. Dillman RO, Church C, Oldham RK, et al. Inpatient continuous-infusion interleukin-2 in 788 patients with cancer. The National Biotherapy Study Group experience. Cancer 1993;71:2358.
10. Sondel PM, Kohler PC, Hank JA, et al. Clinical and immunological effects of recombinant interleukin-2 given by repetitive weekly cycles to patients with cancer. Cancer Res 1988;48:2561.
11. Sosman JA, Kohler PC, Hank J, et al. Repetitive weekly cycles of recombinant human interleukin-2: Responses of renal carcinoma with acceptable toxicity. J Natl Cancer Inst 1988;80:60.
12. Sosman JA, Kohler PC, Hank JA, et al. Repetitive weekly cycles of interleukin-2. Clinical and immunologic effects of dose, schedule, and addition of indomethacin. J Natl Cancer Inst 1988;80:1451.
13. Voss SD, Weil-Hillman G, Hank JA, et al. The clinical immunobiology of interleukin-2: Potential modified uses for improved cancer treatment. Bull NY Acad Med 1989;65:93.
14. Hank JA, Weil-Hillman G, Surfus JE, et al. Addition of interleukin-2 in vitro augments detection of lymphokine-activated killer activity generated in vivo. Cancer Immunol Immunother 1990;31:53.
15. Horton SA, Oldham RK, Yannelli JR. Generation of human lymphokine-activated killer cells following brief exposure to high-dose interleukin-2. Cancer Res 1990;50:1686.
16. Parshad R, Kapoor S, Gupta SD, et al. Does famotidine enhance tumor infiltrating lymphocytes in breast cancer? Results of a randomized prospective pilot study. Acta Oncol 2002;41:362.
17. Tsunoda T, Tanimura H, Yamaue H, et al. In vitro augmentation of the cytotoxic activity of peripheral blood mononuclear cells and tumor-infiltrating lymphocytes by famotidine in cancer patients. Int J Immunopharmac 1992;14:75.
18. Mitchell MS, Kempf RA, Harel W, et al. Low-dose cyclophosphamide and low-dose interleukin-2 for malignant melanoma. Bull NY Acad Med 1989;65:128.
19. Quan WDY Jr, Quan FM. Outpatient experience with moderate dose bolus interleukin-2 in metastatic malignant melanoma and kidney cancer. J Immunother 2003;26:286.
20. Osband ME, Carpinito GA, Levine SI, et al. Successful adoptive immunotherapy of renal cell carcinoma with in vitro immunized autologous lymphocytes and cimetidine. World J Urol 1989;4:217.
21. Weinrich DM, Rosenberg SA. Response rates of patients with metastatic melanoma to high-dose intravenous interleukin-2 after prior exposure to alpha- interferon or low-dose interleukin-2. J Immunother 2002;25:185.
22. Quan WDY Jr, Quan FM. Bolus followed by continuous infusion interleukin-2 in patients with metastatic malignant melanoma and kidney cancer previously treated with interleukin-2. Cancer Biother Radiopharm 2003;18:535.
23. Domzig W, Stadler BM, Herberman RB. Interleukin-2 dependence of human natural killer (LAK) cell activity. J Immunol 1983;130:1970.
24. Yang JC, Rosenberg SA. An ongoing prospective randomized comparison of interleukin-2 regimens for the treatment of metastatic renal cell carcinoma. Cancer J Sci Am 1997;3(Suppl. 1):S79.
25. Weil-Hillman G, Frisch P, Prieve AF, et al. Lymphokine-activated killer activity induced by In vivo interleukin-2 therapy: Predominant role for lymphocytes with increased expression of CD2 and Leu 19 antigens but negative expression of CD16 antigens. Cancer Res 1989;49:3680.
26. McMannis JD, Fisher RI, Creekmore SP, et al. In vivo effects of recombinant IL-2: I. Isolation of circulating Leu-19+ lymphokine-activated killer effector cells from cancer patients receiving recombinant IL-2. J Immunol 1988;140:1335.
27. Dillman RO, Wiemann MC, VanderMolen LA, et al. Hybrid high-dose bolus/continuous infusion interleukin-2 in patients with metastatic melanoma: A phase II trial of the Cancer Biotherapy Research Group (formerly the National Biotherapy Study Group). Cancer Biother Radiopharm 1997;12:249.
28. Dillman RO, Wiemann MC, Bury MJ, et al. Hybrid high-dose bolus/continuous infusion interleukin-2 in patients with metastatic renal cell carcinoma: A phase II trial of the National Biotherapy Study Group. Cancer Biother Radiopharm 1997;12:5.
29. Bar MH, Sznol M, Atkins MB, et al. Metastatic malignant melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine-activated killer cells. J Clin Oncol 1990;8:1138.
30. Gambacorti-Passerini C, Hank JA, Albertini MR, et al. A pilot phase II trial of continuous-infusion interleukin-2 followed by lymphokine-activated killer cell therapy and bolus-infusion interleukin-2 in renal cancer. J Immunother 1993;13:43.
31. Quan W Jr, Brick W, Vinogradov M, et al. Repeated cycles with 72-hour continuous infusion interleukin-2 in kidney cancer and melanoma. Cancer Biother Radiopharm 2004;19:350.
32. Lindsey KR, Rosenberg SA, Sherry RM. Impact of the number of treatment courses on the clinical response of patients who receive high-dose bolus interleukin-2. J Clin Oncol 2000;18:1954.